Motherhood after breast cancer: Searching for la dolce vita

Expert Review of Anticancer Therapy

Volumn 11, Issue 2, 2011, Pages 287-298

  Azim Jr , Hatem A ^a   Peccatori, Fedro A ^b   De Azambuja, Evandro ^a   Piccart, Martine J ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

breastfeeding after breast cancer; fertility counseling; fertility preservation; pregnancy after breast cancer

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLLITROPIN; GONADORELIN AGONIST; GOSERELIN; GROWTH HORMONE RECEPTOR; LETROZOLE; LEUPRORELIN; METHOTREXATE; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; TRIPTORELIN;

AMENORRHEA; BREAST CANCER; BREAST FEEDING; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CANCER SURVIVOR; CONGENITAL MALFORMATION; COUNSELING; DRUG MEGADOSE; FEASIBILITY STUDY; FERTILITY; FERTILIZATION IN VITRO; FETUS OUTCOME; HOSPITAL; HUMAN; LOW BIRTH WEIGHT; LOW DRUG DOSE; MOTHER; MULTIPLE CYCLE TREATMENT; NULLIPARA; OOCYTE; PARITY; PERCEPTION; PREGNANCY; PREMATURE LABOR; PROGNOSIS; QUALITY OF LIFE; REVIEW; UNITED STATES;

AMENORRHEA; BREAST FEEDING; BREAST NEOPLASMS; CRYOPRESERVATION; FEMALE; HUMANS; INFERTILITY, FEMALE; META-ANALYSIS AS TOPIC; NEOPLASM RECURRENCE, LOCAL; OVULATION INDUCTION; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY COMPLICATIONS, NEOPLASTIC; REPRODUCTIVE TECHNIQUES, ASSISTED; RISK FACTORS;

EID: 79952122635     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.208     Document Type: Review

References (105)

1. Fredholm H, Eaker S, Frisell J et al. Breast cancer in young women: poor survival despite intensive treatment. PLoS One 4(11), e7695 (2009).
2. Cancello G, Maisonneuve P, Rotmensz N et al. Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. Ann. Oncol. 21(10), 1974-1981 (2010). • Large study demonstrating that young women younger than 35 years of age with triple-negative, luminal-B and HER2-positive breast cancer have a poorer prognosis when compared with older patients with a similar breast cancer subtype.
3. Swanson GM, Lin CS. Survival patterns among younger women with breast cancer: the effects of age, race, stage, and treatment. J. Natl Cancer Inst. Monogr. 16, 69-77 (1994).
4. Colleoni M, Rotmensz N, Robertson C et al. Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann. Oncol. 13(2), 273-279 (2002).
5. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J. Clin. 59(4), 225-249 (2009).
6. Berkowitz GS, Skovron ML, Lapinski RH, Berkowitz RL. Delayed childbearing and the outcome of pregnancy. N. Engl. J. Med. 322(10), 659-664 (1990).
7. Partridge AH, Gelber S, Peppercorn J et al. Web-based survey of fertility issues in young women with breast cancer. J. Clin. Oncol. 22(20), 4174-4183 (2004).
8. Peccatori FA, Azim HA Jr. Pregnancy in breast cancer survivors: a need for proper counseling. Breast (Edinb., Scotland) 18(6), 337-338 (2009).
9. Rippy EE, Karat IF, Kissin MW. Pregnancy after breast cancer: the importance of active counselling and planning. Breast (Edinb., Scotland) 18(6), 345-350 (2009).
10. Peccatori F, Cinieri S, Orlando L, Bellettini G. Subsequent pregnancy after breast cancer. Recent Results Cancer Res. 178, 57-67 (2008).
11. Faddy MJ, Gosden RG, Gougeon A, Richardson SJ, Nelson JF. Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. Hum. Reprod. (Oxford, Engl.) 7(10), 1342-1346 (1992).
12. Gougeon A, Ecochard R, Thalabard JC. Age-related changes of the population of human ovarian follicles: increase in the disappearance rate of non-growing and early-growing follicles in aging women. Biol. Reproduct. 50(3), 653-663 (1994).
13. Partridge AH, Gelber S, Peppercorn J et al. Fertility and menopausal outcomes in young breast cancer survivors. Clin. Breast Cancer 8(1), 65-69 (2008).
14. Partridge A, Gelber S, Gelber RD et al. Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. Eur. J. Cancer 43(11), 1646-1653 (2007).
15. Partridge AH, Ruddy KJ, Gelber S et al. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertil. Steril. 94(2), 638-644 (2010). •• Demonstrates that ovarian reserve is poor in women who resume menstruation following chemotherapy, highlighting that menses is an imperfect surrogate for prediction of future fertility.
16. Abusief ME, Missmer SA, Ginsburg ES, Weeks JC, Partridge AH. The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer 116(4), 791-798 (2010). •• Large study examining the effects of different chemotherapy regimens and trastuzumab on inducing permanent amenorrhea.
17. Burstein HJ, Winer EP. Primary care for survivors of breast cancer. N. Engl. J. Med. 343(15), 1086-1094 (2000).
18. Fornier MN, Modi S, Panageas KS, Norton L, Hudis C. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer 104(8), 1575-1579 (2005).
19. Petrek JA, Naughton MJ, Case LD et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J. Clin. Oncol. 24(7), 1045-1051 (2006).
20. Berliere M, Dalenc F, Malingret N et al. Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel. BMC Cancer 8, 56 (2008).
21. Nechuta S, Paneth N, Velie EM. Pregnancy characteristics and maternal breast cancer risk: a review of the epidemiologic literature. Cancer Causes Control 21(7), 967-989 (2010).
22. Mustacchi P. Ramazzini and Rigoni-Stern on parity and breast cancer. Clinical impression and statistical corroboration. Arch. Int. Med. 108, 639-642 (1961).
23. Albrektsen G, Heuch I, Tretli S, Kvale G. Breast cancer incidence before age 55 in relation to parity and age at first and last births: a prospective study of one million Norwegian women. Epidemiology (Cambridge, Mass.) 5(6), 604-611 (1994).
24. MacMahon B, Cole P, Lin TM et al. Age at first birth and breast cancer risk. Bull. World Health Organ. 43(2), 209-221 (1970).
25. Rosner B, Colditz GA, Willett WC. Reproductive risk factors in a prospective study of breast cancer: the Nurses' Health study. Am. J. Epidemiol. 139(8), 819-835 (1994).
26. Albrektsen G, Heuch I, Hansen S, Kvale G. Breast cancer risk by age at birth, time since birth and time intervals between births: exploring interaction effects. Br. J. Cancer 92(1), 167-175 (2005).
27. Lambe M, Hsieh C, Trichopoulos D et al. Transient increase in the risk of breast cancer after giving birth. N. Engl. J. Med. 331(1), 5-9 (1994).
28. Peterson NB, Huang Y, Newcomb PA et al. Childbearing recency and modifiers of premenopausal breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 17(11), 3284-3287 (2008).
29. Daling JR, Malone KE, Doody DR, Anderson BO, Porter PL. The relation of reproductive factors to mortality from breast cancer. Cancer Epidemiol. Biomarkers Prev. 11(3), 235-241 (2002).
30. Bemis LT, Schedin P. Reproductive state of rat mammary gland stroma modulates human breast cancer cell migration and invasion. Cancer Res. 60(13), 3414-3418 (2000).
31. Polyak K. Pregnancy and breast cancer: the other side of the coin. Cancer Cell 9(3), 151-153 (2006).
32. Asztalos S, Gann PH, Hayes MK et al. Gene expression patterns in the human breast after pregnancy. Cancer Prev. Res. (Phila., PA) 3(3), 301-311 (2010).
33. Asselin-Labat ML, Vaillant F, Sheridan JM et al. Control of mammary stem cell function by steroid hormone signalling. Nature 465(7299), 798-802 (2010).
34. Dontu G, Abdallah WM, Foley JM et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 17(10), 1253-1270 (2003).
35. Dontu G, Al-Hajj M, Abdallah WM, Clarke MF, Wicha MS. Stem cells in normal breast development and breast cancer. Cell Prolif. 36(Suppl. 1), 59-72 (2003).
36. Laban C, Bustin SA, Jenkins PJ. The GH - IGF-I axis and breast cancer. Trends Endocrinol. Metab. 14(1), 28-34 (2003).
37. Cooper DR, Butterfield J. Pregnancy subsequent to mastectomy for cancer of the breast. Ann. Surg. 171(3), 429-433 (1970).
38. Mignot L, Morvan F, Berdah J et al. [Pregnancy after treated breast cancer. Results of a case-control study]. Presse Med. 15(39), 1961-1964 (1986).
39. Ariel IM, Kempner R. The prognosis of patients who become pregnant after mastectomy for breast cancer. Int. Surg. 74(3), 185-187 (1989).
40. Sankila R, Heinavaara S, Hakulinen T. Survival of breast cancer patients after subsequent term pregnancy: 'healthy mother effect'. Am. J. Obstet. Gynecol. 170(3), 818-823 (1994).
41. Malamos NA, Stathopoulos GP, Keramopoulos A, Papadiamantis J, Vassilaros S. Pregnancy and offspring after the appearance of breast cancer. Oncology 53(6), 471-475 (1996).
42. Lethaby AE, O'Neill MA, Mason BH, Holdaway IM, Harvey VJ. Overall survival from breast cancer in women pregnant or lactating at or after diagnosis. Auckland Breast Cancer Study Group. Int. J. Cancer 67(6), 751-755 (1996).
43. Velentgas P, Daling JR, Malone KE et al. Pregnancy after breast carcinoma: outcomes and influence on mortality. Cancer 85(11), 2424-2432 (1999).
44. Birgisson H, Tryggvadottir L, Tulinius H. [The effect of pregnancy on the survival of women diagnosed with breast cancer]. Laeknabladid 86(7/8), 495-498 (2000).
45. Gelber S, Coates AS, Goldhirsch A et al. Effect of pregnancy on overall survival after the diagnosis of early-stage breast cancer. J. Clin. Oncol. 19(6), 1671-1675 (2001).
46. Mueller BA, Simon MS, Deapen D et al. Childbearing and survival after breast carcinoma in young women. Cancer 98(6), 1131-1140 (2003).
47. Blakely LJ, Buzdar AU, Lozada JA et al. Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence. Cancer 100(3), 465-469 (2004).
48. Ives A, Saunders C, Bulsara M, Semmens J. Pregnancy after breast cancer: population based study. Br. Med. J. 334(7586), 194 (2007).
49. Kroman N, Jensen MB, Wohlfahrt J, Ejlertsen B. Pregnancy after treatment of breast cancer - a population-based study on behalf of Danish Breast Cancer Cooperative Group. Acta Oncol. 47(4), 545-549 (2008).
50. Largillier R, Savignoni A, Gligorov J et al. Prognostic role of pregnancy occurring before or after treatment of early breast cancer patients aged <35 years: a GET(N)A Working Group analysis. Cancer 115(22), 5155-5165 (2009).
51. Kranick JA, Schaefer C, Rowell S et al. Is pregnancy after breast cancer safe? Breast J. 16(4), 404-411 (2010).
52. Verkooijen HM, Lim GH, Czene K et al. Effect of childbirth after treatment on long-term survival from breast cancer. Br. J. Surg. 97(8), 1253-1259 (2010).
53. Azim HA Jr, Santoro L, Pavlidis N et al. Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies. Eur. J. Cancer 47(1), 74-83 (2011). •• A large meta-analysis involving approximately 20,000 patients showing the safety of pregnancy in women with a history of breast cancer diagnosis.
54. Gorman JR, Roesch SC, Parker BA et al. Physical and mental health correlates of pregnancy following breast cancer. Psychooncology 19(5), 517-524 (2010).
55. Pagani O, Price KN, Gelber RD et al. Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century. Breast Cancer Res. Treat. 117(2), 319-324 (2009).
56. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472), 1687-1717 (2005).
57. Gerber B, Dieterich M, Muller H, Reimer T. Controversies in preservation of ovary function and fertility in patients with breast cancer. Breast Cancer Res. Treat. 108(1), 1-7 (2008).
58. Mills JL, Simpson JL, Driscoll SG et al. Incidence of spontaneous abortion among normal women and insulin-dependent diabetic women whose pregnancies were identified within 21 days of conception. N. Engl. J. Med. 319(25), 1617-1623 (1988).
59. Langagergaard V, Gislum M, Skriver MV et al. Birth outcome in women with breast cancer. Br. J. Cancer 94(1), 142-146 (2006).
60. Dalberg K, Eriksson J, Holmberg L. Birth outcome in women with previously treated breast cancer - a population-based cohort study from Sweden. PLoS Med. 3(9), e336 (2006).
61. Agostoni C, Trojan S, Bellu R et al. Developmental quotient at 24 months and fatty acid composition of diet in early infancy: a follow up study. Arch. Dis. Child. 76(5), 421-424 (1997).
62. Anderson JW, Johnstone BM, Remley DT. Breast-feeding and cognitive development: a meta-analysis. Am. J. Clin. Nutr. 70(4), 525-535 (1999).
63. Zembo CT. Breastfeeding. Obstet. Gynecol. Clin. North Am. 29(1), 51-76 (2002).
64. Kjos SL, Henry O, Lee RM, Buchanan TA, Mishell DR Jr. The effect of lactation on glucose and lipid metabolism in women with recent gestational diabetes. Obstet. Gynecol. 82(3), 451-455 (1993).
65. Gorman JR, Usita PM, Madlensky L, Pierce JP. A qualitative investigation of breast cancer survivors' experiences with breastfeeding. J. Cancer Surviv. 3(3), 181-191 (2009).
66. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 360(9328), 187-195 (2002).
67. Jernstrom H, Lubinski J, Lynch HT et al. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J. Natl Cancer Inst. 96(14), 1094-1098 (2004).
68. McNeilly AS, Tay CC, Glasier A. Physiological mechanisms underlying lactational amenorrhea. Ann. NY Acad. Sci. 709, 145-155 (1994).
69. Bercovich D, Goodman G. Pregnancy and lactation after breast cancer elevate plasma prolactin, do not shorten and may prolong survival. Medical Hypoth. 73(6), 942-947 (2009).
70. Turkington RW, Underwood LE, van Wyk JJ. Elevated serum prolactin levels after pituitary-stalk section in man. N. Engl. J. Med. 285(13), 707-710 (1971).
71. Nevalainen MT, Xie J, Torhorst J et al. Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J. Clin. Oncol. 22(11), 2053-2060 (2004).
72. Wang DY, Hampson S, Kwa HG et al. Serum prolactin levels in women with breast cancer and their relationship to survival. Eur. J. Cancer Clin. Oncol. 22(4), 487-492 (1986).
73. Tran TH, Utama FE, Lin J et al. Prolactin inhibits BCL6 expression in breast cancer through a Stat5a-dependent mechanism. Cancer Res. 70(4), 1711-1721 (2010).
74. Azim HA Jr, Bellettini G, Gelber S, Peccatori FA. Breast-feeding after breast cancer: if you wish, madam. Breast Cancer Res. Treat. 114(1), 7-12 (2009). • Comprehensive review on the safety and feasibility of breastfeeding in breast cancer survivors including an original survival analysis - the only in literature - comparing the overall survival of women who became pregnant following breast cancer diagnosis according to breastfeeding status.
75. Azim HA Jr, Bellettini G, Liptrott SJ et al. Breastfeeding in breast cancer survivors: pattern, behaviour and effect on breast cancer outcome. Breast 19(6), 527-531 (2010).
76. Helewa M, Levesque P, Provencher D et al. Breast cancer, pregnancy, and breastfeeding. J. Obstet. Gynaecol. Can. 24(2), 164-180; quiz 181-164 (2002).
77. Higgins S, Haffty BG. Pregnancy and lactation after breast-conserving therapy for early stage breast cancer. Cancer 73(8), 2175-2180 (1994).
78. Moran MS, Colasanto JM, Haffty BG et al. Effects of breast-conserving therapy on lactation after pregnancy. Cancer J. (Sudbury, Mass.) 11(5), 399-403 (2005).
79. Tralins AH. Lactation after conservative breast surgery combined with radiation therapy. Am. J. Clin. Oncol. 18(1), 40-43 (1995).
80. Schnitt SJ, Goldwyn RM, Slavin SA. Mammary ducts in the areola: implications for patients undergoing reconstructive surgery of the breast. Plast. Reconstr. Surg. 92(7), 1290-1293 (1993).
81. Camune B, Gabzdyl E. Breast-feeding after breast cancer in childbearing women. J. Perinat. Neonatal Nurs. 21(3), 225-233 (2007).
82. Ing R, Petrakis NL, Ho JH. Unilateral breast-feeding and breast cancer. Lancet 2(8029), 124-127 (1977).
83. Riordan J, Gill-Hopple K, Angeron J. Indicators of effective breastfeeding and estimates of breast milk intake. J. Hum. Lact. 21(4), 406-412 (2005).
84. Anchan RM, Ginsburg ES. Fertility concerns and preservation in younger women with breast cancer. Crit. Rev. Oncol. Hematol. 74(3), 175-192 (2010).
85. Fox KR, Scialla J, Moore H. Preventing chemotherapy-related amenorrhea using leuprolide during adjuvant chemotherapy for early-stage breast cancer. Proc. Am. Soc. Clin. Oncol. 22 (2003) (Abstract 50).
86. Del Mastro L, Catzeddu T, Boni L et al. Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. Ann. Oncol. 17(1), 74-78 (2006).
87. Recchia F, Saggio G, Amiconi G et al. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer 106(3), 514-523 (2006).
88. Urruticoechea A, Arnedos M, Walsh G, Dowsett M, Smith IE. Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC). Breast Cancer Res. Treat. 110(3), 411-416 (2008).
89. Ismail-Khan R, Minton S, Cox C et al. Preservation of ovarian function in young women treated with neoadjuvant chemotherapy for breast cancer: a randomized trial using the GnRH agonist (triptorelin) during chemotherapy. J. Clin. Oncol. 26(20 Suppl.), (2008) (Abstract 524).
90. Badawy A, Elnashar A, El-Ashry M, Shahat M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil. Steril. 91(3), 694-697 (2009).
91. Peccatori F, Demeestere I. GnRH analogue for chemotherapy-induced ovarian damage: too early to say? Fertil. Steril. 92(2), e33; author reply e34 (2009).
92. Oktay K, Sonmezer M. Questioning GnRH analogs for gonadal protection in cancer patients. Fertil. Steril. 92(2), e32; author reply e34 (2009).
93. Del Mastro L, Boni L, Michelotti A et al. Role of luteinizing hormone-releasing hormone analog (LHRHa) triptorelin (T) in preserving ovarian function during chemotherapy for early breast cancer patients: results of a multicenter Phase III trial of Gruppo Italiano Mammella (GIM) group. J. Clin. Oncol. 28(15 Suppl.), (2010) (Abstract 528). •• Largest study to date evaluating the effect of luteinizing hormone-releasing hormone agonists, demonstrating an apparent positive effect on preserving ovarian function in young women receiving chemotherapy.
94. Azem F, Amit A, Merimsky O, Lessing JB. Successful transfer of frozen - thawed embryos obtained after subtotal colectomy for colorectal cancer and before fluorouracil-based chemotherapy. Gynecologic Oncol. 93(1), 263-265 (2004).
95. Ginsburg ES, Yanushpolsky EH, Jackson KV. In vitro fertilization for cancer patients and survivors. Fertil. Steril. 75(4), 705-710 (2001).
96. Oktay K, Buyuk E, Davis O et al. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum. Reprod. (Oxford, Engl.) 18(1), 90-95 (2003).
97. Ayhan A, Salman MC, Celik H et al. Association between fertility drugs and gynecologic cancers, breast cancer, and childhood cancers. Acta Obstet. Gynecol. Scand. Suppl. 83(12), 1104-1111 (2004).
98. Omland AK, Fedorcsak P, Storeng R et al. Natural cycle IVF in unexplained, endometriosis-associated and tubal factor infertility. Hum. Reprod. (Oxford, Engl.) 16(12), 2587-2592 (2001).
99. Oktay K. Further evidence on the safety and success of ovarian stimulation with letrozole and tamoxifen in breast cancer patients undergoing in vitro fertilization to cryopreserve their embryos for fertility preservation. J. Clin. Oncol. 23(16), 3858-3859 (2005).
100. Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J. Clin. Oncol. 23(19), 4347-4353 (2005).
101. Oktay K, Hourvitz A, Sahin G et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J. Clin. Endocrinol. Metab. 91(10), 3885-3890 (2006).
102. Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J. Clin. Oncol. 26(16), 2630-2635 (2008). •• Study demonstrating the safety and feasibility of using letrozole and gonadotropins in ovarian stimulation of young breast cancer patients prior to starting adjuvant chemotherapy.
103. Lee SJ, Schover LR, Partridge AH et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J. Clin. Oncol. 24(18), 2917-2931 (2006).
104. Center for Disease Control and Prevention (CDC): 2004 Assisted Reproductive Technology (ART) Report www.cdc.giv/art/ART2004/section3.htm
105. ClinicalTrials.gov www.clinicaltrials.gov